FBRX — Recent News Coverage
All news mentioning FBRX in ESEN's AI-graded feed
News stories with FBRX as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on FBRX. See /coverage/FBRX for the 30-day aggregate.
INSIDERMONKEY.COM
·
2026-07-29
HIGH
BULLISH
CORR0.72
argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks
$ARGX
$FBRX
◈ ESEN AI
argenx announced a $2.2 billion acquisition of Forte Biosciences, signaling aggressive M&A momentum in the biopharma sector. This deal represents a substantial capital deployment and signals management confidence in vit…
RTTNEWS.COM
·
2026-07-28
NEUTRAL
BULLISH
CORR0.45
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
$GOSS
$OMER
$FBRX
$ENTX
◈ ESEN AI
GOSS advances toward a critical regulatory milestone with its planned Seralutinib NDA submission scheduled for September, representing a key inflection point for the company's pipeline. This regulatory progress typicall…
FINANCE.YAHOO.COM
·
2026-07-27
HIGH
BULLISH
CORR0.72
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx
$FBRX
$ARGX
◈ ESEN AI
FBRX surged 39.2% on announcement of a $2.2 billion all-cash acquisition by ARGX, representing a significant M&A event in the clinical-stage biotech space. The transaction premium reflects argenx's strategic interest in…
RTTNEWS.COM
·
2026-07-27
HIGH
BULLISH
CORR0.72
Argenx To Buy Forte Biosciences In Around $2.2 Bln Cash Deal; Forte Biosciences Shares Climb
$ARGX
$FBRX
◈ ESEN AI
Argenx has announced a $2.2 billion cash acquisition of Forte Biosciences at $77 per share, representing a significant consolidation move in the immunology and dermatology therapeutic space. This deal signals accelerate…
MANILATIMES.NET
·
2026-07-27
NEUTRAL
BULLISH
CORR0.58
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
$ARGX
$FBRX
◈ ESEN AI
argenx announced an acquisition of Forte Biosciences, securing the anti-CD122 antibody FB102—a novel immunology candidate currently in Phase 1b trials. This transaction builds upon argenx's existing strategic investment…
BUSINESSWIRE
·
2026-07-27
HIGH
BULLISH
CORR0.72
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
$ARGX
$FBRX
◈ ESEN AI
argenx announced a $2.2 billion cash acquisition of Forte Biosciences at $77 per share, a significant M&A event in the immunology space. The deal adds FB102, a first-in-class anti-CD122 antibody, to argenx's existing im…
FINANCE.YAHOO.COM
·
2026-07-21
NEUTRAL
BULLISH
CORR0.72
Should You Be Bullish on Forte Biosciences (FBRX)
$FBRX
◈ ESEN AI
Forte Biosciences (FBRX) is receiving favorable positioning commentary from Fred Alger Management's mid-cap equity strategy, suggesting institutional interest in the biotech name. The framing within a fund letter discus…
RTTNEWS.COM
·
2026-07-19
LOW
NEUTRAL
CORR0.15
5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & More
$SION
$FBRX
$NKTR
$AMRX
◈ ESEN AI
This article presents a retrospective analysis of five biotech and small-cap securities that experienced significant appreciation, with NKTR leading at +869% and FBRX at +306%. The piece frames value investing through J…
SEEKINGALPHA.COM
·
2026-07-13
NEUTRAL
BULLISH
CORR0.35
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow (NASDAQ:FBRX) 2026-07-13
$FBRX
◈ ESEN AI
FBRX has released positive Phase 1b trial data for FB102, its investigational treatment targeting vitiligo. The positive efficacy signals and mechanism-of-action presentation represent progress in the clinical developme…
SEEKINGALPHA.COM
·
2026-07-10
NEUTRAL
BULLISH
CORR0.45
Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet (NASDAQ:FBRX)
$FBRX
◈ ESEN AI
Forte Biosciences (FBRX) is shifting its narrative from a single-asset company to a platform-driven biotech story. The FDA candidate FB102 demonstrates therapeutic efficacy across multiple indications—vitiligo and celia…
SEEKINGALPHA.COM
·
2026-07-09
NEUTRAL
BULLISH
CORR0.42
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
$FBRX
◈ ESEN AI
Forte Biosciences (FBRX) reported positive Phase 1b clinical trial results for FB102, its investigational treatment targeting vitiligo, a chronic depigmentation disorder affecting millions globally. The disclosed mechan…
EXPLORE OTHER FILTERS